Key result
Very high-risk HFA-ICOS score is linked to ~5.8-fold higher mortality after R-COMP chemotherapy.
Why the study?
The real-world validation of the HFA-ICOS risk score for patients with non-Hodgkin lymphoma treated with non-PEGylated liposomal anthracycline remains limited.
Does the HFA-ICOS risk score effectively stratify mortality and cardiotoxicity risk in patients with newly diagnosed non-Hodgkin lymphoma receiving non-PEGylated doxorubicin therapy?
Cohort (n=265)
Does the HFA-ICOS risk score effectively stratify mortality and cardiotoxicity risk in patients with newly diagnosed non-Hodgkin lymphoma receiving non-PEGylated doxorubicin therapy?
The HFA-ICOS risk score effectively stratifies the risk of mortality and cardiovascular events in patients with non-Hodgkin lymphoma undergoing non-PEGylated doxorubicin therapy, supporting its real-world clinical utility.
Answers are grounded in this paper and cite their sources.
Very high HFA-ICOS risk warrants close surveillance on R-CHOP; leaves open whether risk-adapted prevention improves survival.
Background Elderly patients with non-Hodgkin lymphoma, or patients with pre-existing cardiovascular comorbidities, are frequently treated with chemotherapy regimens containing non-PEGylated liposomal anthracycline, in order to reduce cardiotoxicity incidence. For patients candidate to anthracycline, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines recommend risk stratification through established proformas, but their real-world validation for patients candidate to liposomal anthracycline remains limited. Methods We retrospectively collected data on patients with newly diagnosed non-Hodgkin lymphoma treated with rituximab, cyclophosphamide, non-PEGylated doxorubicin, vincristine, and prednisone (R-COMP) between 2014 and 2025. Baseline demographics, cardiovascular history, echocardiographic and laboratory parameters, and baseline therapy were recorded. Patients were stratified into risk categories according to the Heart Failure Association International Cardio-Oncology Society (HFA-ICOS) score. Outcomes included overall survival (OS), cardiovascular events occurrence (including asymptomatic left ventricular dysfunction, new-onset or worsening heart failure and acute coronary syndrome) and progression-free survival (PFS). Results The cohort consisted of 265 patients [median age 73 years (69 – 77); 51% males]; 41% were classified as moderate risk, 55% as high risk, and 4% as very high risk. During a median follow-up of 29 months, 38 patients (14%) died. OS and cardiovascular events occurrence significantly differed across HFA-ICOS risk categories (p=0.005 and p<0.0001, respectively). Very high-risk patients exhibited substantially higher hazards of mortality (HR 5.8) and cardiovascular events (HR 40.4). Cardioprotective therapy at baseline did not influence cardiovascular outcomes. Conclusions The HFA-ICOS score effectively stratifies mortality and cardiotoxicity risk among R-COMP–treated patients. These findings support its application in routine treatment of lymphomas requiring anthracycline-based therapy.
No takes yet. Share an insight, caveat, or question.
Camilli et al. (2026) conducted a cohort in Non-Hodgkin lymphoma (n=265). Very high HFA-ICOS risk score vs. Lower HFA-ICOS risk categories was evaluated on overall survival (OS) (HR 5.8, p=0.005). Very high-risk classification by the HFA-ICOS score was associated with substantially higher hazards of mortality (HR 5.8) and cardiovascular events (HR 40.4) in patients treated with R-COMP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: